Celldex Therapeutics (CLDX) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $36.0 million.
- Celldex Therapeutics' Cash & Equivalents fell 99.45% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 99.45%. This contributed to the annual value of $28.4 million for FY2024, which is 1855.0% down from last year.
- As of Q3 2025, Celldex Therapeutics' Cash & Equivalents stood at $36.0 million, which was down 99.45% from $23.0 million recorded in Q2 2025.
- Celldex Therapeutics' 5-year Cash & Equivalents high stood at $115.1 million for Q1 2024, and its period low was $17.1 million during Q1 2025.
- Moreover, its 5-year median value for Cash & Equivalents was $34.8 million (2023), whereas its average is $40.2 million.
- As far as peak fluctuations go, Celldex Therapeutics' Cash & Equivalents skyrocketed by 29768.61% in 2021, and later crashed by 8510.91% in 2025.
- Over the past 5 years, Celldex Therapeutics' Cash & Equivalents (Quarter) stood at $39.1 million in 2021, then fell by 24.82% to $29.4 million in 2022, then rose by 18.3% to $34.8 million in 2023, then decreased by 18.55% to $28.4 million in 2024, then rose by 27.09% to $36.0 million in 2025.
- Its Cash & Equivalents stands at $36.0 million for Q3 2025, versus $23.0 million for Q2 2025 and $17.1 million for Q1 2025.